Advertisement
Advertisement
RCEL
Avita Medical, Inc. Common Stock
7.77
USDSponsored
+3.02
+63.58%
Aug 07, 15:59 UTC -4
Closed
After-Market
7.83
+0.06
+0.82%
RCEL Earnings Reports
Positive Surprise Ratio
RCEL beat 8 of 18 last estimates.
44%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$20.98M
/-$0.29
Implied change from Q2 26 (Revenue/ EPS)
-3.33%
/+16.00%
Implied change from Q3 25 (Revenue/ EPS)
+22.95%
/-36.96%
Avita Medical, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, RCEL reported earnings of -0.25 USD per share (EPS) for Q2 26, beating the estimate of -0.29 USD, resulting in a 14.50% surprise. Revenue reached 21.70 million, compared to an expected 20.57 million, with a 5.49% difference. The market reacted with a +63.58% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 20.98 million USD, implying an increase of 16.00% EPS, and decrease of -3.33% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Guardian Pharmacy Services, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.28
Surprise
+3.76%
FAQ
What were Avita Medical, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Avita Medical, Inc. Common Stock reported EPS of -$0.25, beating estimates by 14.5%, and revenue of $21.70M, 5.49% above expectations.
How did the market react to Avita Medical, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 63.58%, changed from $4.75 before the earnings release to $7.77 the day after.
When is Avita Medical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Avita Medical, Inc. Common Stock's next earnings report?
Based on 5
analysts, Avita Medical, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $20.98M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement